ChemPartner
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cleverbridge Appoints Markus Scheuermann as Chief Financial Officer12.2.2025 05:00:00 CET | Press release
Seasoned Finance Leader Brings 20+ Years of Expertise in Financial Strategy, M&A and Digital Transformation to Cleverbridge COLOGNE, GERMANY & CHICAGO, IL / ACCESS Newswire / February 12, 2025 / Cleverbridge, a leading provider of ecommerce and billing solutions for global software and SaaS companies, today announced the appointment of Markus Scheuermann as Chief Financial Officer, effective as of April 1, 2025.Markus Scheuermann Scheuermann is a seasoned senior executive with over 20 years of experience in financial strategy, business development, M&A, and digital transformation within high-performing technology organizations. Most recently, he served as Chief Financial Officer at Thinkproject Group and has previously held key leadership roles at HolidayCheck Group, Hubert Burda Media, eBay, and McKinsey & Company. Markus will report directly to Wendi Sturgis, Cleverbridge CEO, and be part of an executive leadership team that includes CRO Kevin Feagan, CTO Radu Immenroth, and CHRO Ale
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 202411.2.2025 11:45:00 CET | Press release
Uncertain outlook for 2025 as new immigration policies are implemented PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 11, 2025 / A new CGFNS International report indicates that a robust annual rate of nurse migration into the United States held steady in 2024 as healthcare systems continued to look to foreign-educated nurses to help address persistent staffing shortages.CGFNS International 2024 Nurse Migration Report However, in its 2024 Nurse Migration Report, the organization also said the current high rates were likely unsustainable amid persisting visa retrogression and caps on employment-based green cards for nurses, along with new immigration policies being implemented by the Trump Administration that will likely have further impact on visa availability and processing times. CGFNS, a global health workforce non-profit that verifies credentials of healthcare professionals for immigration authorities and state licensing boards, reported that in fiscal year 2024 it received
An Incredible KLAS Triple-Award Win for AGFA HealthCare!10.2.2025 09:00:00 CET | Press release
MORTSEL, BE / ACCESS Newswire / February 10, 2025 / AGFA HealthCare proudly celebrates a remarkable KLAS triple-win, securing two #1 Best in KLAS Awards for XERO® Viewer and VNA, alongside the KLAS Most Improved Software Product for 2025. "To receive a KLAS Award is one of the most notable wins for AGFA HealthCare, and a testament to the hard work we invest into our flagship platform. More importantly, it reflects the trust and recognition from our customers. Their success is our success, and to receive two such awards is simply breathtaking." - Nathalie McCaughley, President, AGFA HealthCare The Best in KLAS report recognizes software and service providers who excel in supporting healthcare professionals and patient care. Based on extensive customer feedback and evaluations, these awards highlight AGFA HealthCare's unwavering commitment to innovation and excellence. For 2025, AGFA HealthCare's Enterprise Imaging XERO® Viewer leads the Universal Viewer (Imaging) category for the second
Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings10.2.2025 07:50:00 CET | Press release
Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence. "The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. His
Registration Now Open for World of Coffee 2025 in Geneva: The Premier Event for Coffee Professionals6.2.2025 09:00:00 CET | Press release
Join Over 13,000 Attendees and 430+ Exhibitors at Europe's Largest Specialty Coffee Trade Show GENEVA, SWITZERLAND / ACCESS Newswire / February 6, 2025 / World of Coffee, the essential event for coffee professionals, enthusiasts, and innovators from around the globe will have a 2025 edition in Geneva, Switzerland, at the Palexpo SA, June 26-28. Following the record-breaking success of World of Coffee in Copenhagen, this flagship coffee trade show is set to welcome over 13,000 coffee professionals from 160+ countries for three days of business, networking, and education. Produced by the Specialty Coffee Association (SCA), the trade show and conference are proudly supported by Host Sponsor BTW Water + More; Platinum Sponsor Barista Attitude; Diamond Sponsor Nestlé Professional; and Gold Sponsor Alpro. Café de Colombia will be featured as the Portrait Country with unique cultural activations, and a pop-up café experience. "Geneva is the ideal location for hosting our flagship European tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom